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Aims Highly active antiretroviral therapy (HAART) dramatically reduces human immunodeficiency virus (HIV)-associated mor-
bidity and mortality, but adverse effects of HAART are becoming an increasing challenge, especially in the setting of acute
coronary syndromes (ACS). We thus performed a comprehensive review of studies focusing on ACS in HIV patients.
Methods
and results
MEDLINE/PubMed was systematically screened for studies reporting on ACS in HIV patients. Baseline, treatment, and
outcome data were appraised and pooled with random-effect methods computing summary estimates [95% confi-
dence intervals (CIs)]. A total of 11 studies including 2442 patients were identified, with a notably low prevalence
of diabetes [10.86 (4.11, 17.60); 95% CI]. Rates of in-hospital death were 8.00% (2.8, 12.5; 95% CI), ascribable to
cardiovascular events for 7.90% (2.43, 13.37; 95% CI), with 2.31% (0.60, 4.01; 95% CI) developing cardiogenic
shock. At a median follow-up of 25.50 months (11.25, 42; 95% CI), no deaths were recorded, with an incidence
of 9.42% of acute myocardial infarction (2.68, 16.17; 95% CI) and of 20.18% (9.84, 30.51; 95% CI) of percutaneous
coronary revascularization. Moreover, pooled analysis of the studies reporting incidence of acute myocardial infarction in
patients exposed to protease inhibitors showed an overall significant risk of 2.68 (odds ratio 1.89, 3.89; 95% CI).
Conclusion Human immunodeficiency virus patients admitted for ACS face a substantial short-term risk of death and a significant
long-term risk of coronary revascularization and myocardial infarction, especially if receiving protease inhibitors.
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Introduction
Antiretroviral therapies dramatically reduced human immunodefi-
ciency virus (HIV)-associated morbidity and mortality.1 Conse-
quently, detrimental effects of both disease progression and
antiretroviral therapy are becoming an increasing challenge for
physicians managing this high-risk subset of patients.2
In the USA, cardiovascular disease represents the third cause of
death or hospitalization for these patients.3 Coronary artery
disease is an emerging complication, related both to traditional
risk factors and to specific features of these patients. Actually
smoking and hypertriglyceridaemia are more common than
among non-HIV patients, while both the heightened proinflamma-
tory state and antiretroviral drugs4– 8 offer a substrate for the devel-
opment of premature atherosclerosis and atherothrombosis.9– 11
Many studies have provided features and outcomes with acute
coronary artery disease in HIV patients, and the influence of anti-
retroviral therapy in them, providing notable results, often limited
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by the small number of patients. Especially, some reports demon-
strated a higher incidence of acute coronary syndromes (ACS) in
patients under treatment with antiretroviral drugs, in particular
protease inhibitors.12,13
Thus, a meta-analysis was performed to critically appraise risk
factors and outcomes of these patients, and their relationship
with antiretroviral drugs.
Methods
The present research was elaborated according to the current guide-
lines, including the recent Preferred Reporting Items for Systematic
reviews and Meta-Analyses (PRISMA) amendment to the Quality of
Reporting of Meta-analyses (QUOROM) statement, and recommenda-
tions from The Cochrane Collaboration and Meta-analysis Of Obser-
vational Studies in Epidemiology (MOOSE).14 –17 No language
restriction was applied.
Search strategy and study selection
Pertinent articles were searched in Medline, Cochrane Library, Biomed
Central, and Google Scholar in keeping with established methods15
with Mesh strategy and with terms related to HIV patients admitted
with a diagnosis of ACS: (coronary AND (stent* OR ptca OR angio-
plasty OR cabg OR (bypass AND (graft* OR surgery)) AND (hiv
OR aids OR (human AND immunodeficiency AND virus)). Studies ap-
praising only HIV patients or HIV and non-HIV patients were included.
Two independent reviewers (G.B.-Z. and F.D.) first screened
retrieved citations at the title and/or abstract level, with divergences
resolved after consensus. If potentially pertinent, they were then
appraised as complete reports according to the following explicit se-
lection criteria. Studies were included if investigating HIV patients pre-
senting with ACS, while exclusion criteria were (i) non-human setting,
(ii) duplicate reporting (in which case the manuscript reporting the
largest sample of patients with HIV was selected), or (iii) HIV patients
undergoing cardiac surgical procedure other than for ACS.
Data extraction
Two unblinded independent reviewers (G.B.-Z. and F.D.) abstracted the
following data on pre-specified forms: authors, journal, and year of pub-
lication, location of the study group, baseline features, death, myocardial
infarction, and revascularization. Endpoints of interest were incidence of
adverse outcomes and their relationship to antiretroviral therapies.
Rates of death, of cardiovascular death, and of cardiogenic shock
were appraised. Moreover, at follow-up, rates of myocardial infarction,
evaluated according to European Guidelines,16 and of percutaneous
coronary revascularization (both repeat revascularization on the
target vessel/lesion and on de novo stenosis) were evaluated.
Internal validity and quality appraisal
Unblinded independent reviewers (G.B.-Z. and F.D.) evaluated the
quality of included studies on pre-specified forms. Modifying the
MOOSE items to take into account the specific features of included
studies,17 we separately abstracted and appraised study design,
setting, data source, as well as risk of analytical, selection, adjudication,
detection, and attrition bias (expressed as low, moderate, or high risk
of bias, as well as incomplete reporting leading to inability to ascertain
the underlying risk of bias). Moreover, we awarded overall credibility of
studies included to summarized previous features. Zero points were
assigned for retrospective design and one-centre study, and one for
prospective arrangement and for a multicentre setting. Moreover,
two points were ascribed for low risk of bias, one for moderate risk,
and zero for high risk or unclear. If the sum of these scores was 10,
a very high credibility was granted, if it was between 7 and 9 high,
between 4 and 6 moderate, between 1 and 3 low, and 0 very low.
Data analysis and synthesis
Continuous variables are reported as mean (standard deviation) or
median (range). Categorical variables are expressed as n/N (%). Statis-
tical pooling was performed according to a random-effect model with
generic inverse-variance weighting, computing risk estimates with 95%
confidence intervals (CIs), using RevMan 5 (The Cochrane Collabor-
ation, The Nordic Cochrane Centre, and Copenhagen, Denmark). A
small study bias was appraised by graphical inspection of funnel
plots. Standard hypothesis testing was set at the two-tailed 0.05 level.
Results
A total of 236 citations were first screened and appraised at the
abstract level; 19 articles were selected, among which 4 were
excluded because of investigating also non-coronary cardiac
surgery,18–21 three because of including HIV patients undergoing
percutaneous coronary intervention also in stable clinical settings,
1,22,23 and 2 because of investigating baseline features of HIV
patients.4,24 Finally, 11 studies were included in our
review2,12,13,19,25– 31 (Figure 1).
The methodological assessment is reported in Table 1, showing
an overall good quality of the selected studies, most of them being
prospective, half of them multicentre, without a high risk of ana-
lysed bias. Moreover, for each study, definitions of adverse
events and single follow-up were evaluated (see Supplementary
material online, Appendix Table SA).
A total of 2442 patients were included, showing at pooled ana-
lysis an overall average incidence of traditional cardiovascular risk
factors, except for diabetes [10.86 (4.11, 17.60); 95% CI] (Table 2).
Pooled analysis of HIV disease characteristics are reported in
Table 3, showing a time from HIV diagnosis to ACS of 7.45 years
(2.38, 12.51; 95% CI), with most of the patients exposed to nucleo-
side reverse-transcriptase inhibitors [84.23% (74.15, 94.3; 95% CI)]
and protease inhibitors [66.21% (59.77, 72.65; 95% CI)].
At admission, most patients presented with ST-segment eleva-
tion myocardial infarction (STEMI) [57.19% (47.64, 66.75; 95%
CI)], with one-vessel disease as the most angiographic presentation
[52.83% (34.83, 70.83; 95% CI)], and percutaneous transluminal
coronary angioplasty as the most exploited revascularization strat-
egy [54.23% (38.97, 69.49; 95% CI)] (Table 4).
Figure 1 Review profile.
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Rates of in-hospital death (Figure 2) were 8.00% (2.8, 12.5; 95%
CI), ascribable to cardiovascular events for 7.90% (2.43, 13.37; 95%
CI), with 2.31% (0.60, 4.01; 95% CI) developing cardiogenic shock.
At a median follow-up of 25.50 months (11.25, 42; 95% CI), no
deaths were recorded, with an incidence of 9.42% of acute myo-
cardial infarction (2.68, 16.17; 95% CI) and of 20.18% (9.84,
30.51; 95% CI) of percutaneous coronary revascularization.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Cardiovascular evaluation
Pooled analysis (95% CI)a
Age (years) 61 (58, 64)
Male gender 80.45 (77.22, 83.69)
Hypertensive patients 22.29 (14.23, 30.34)
Dyslipidaemic patients 42.50 (33.35, 51.64)
Patients with hypertriglyceridaemia 45.03 (23.68, 66.38)
Diabetic mellitus type 2 patients 10.86 (4.11, 17.60)
Patients actual or previous smoker 60.30 (56.62, 63.99)
aAll data reported as mean or percentages.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .




Time from diagnosis of HIV infection (years) 7.45 (2.38, 12.51)
Median CD4+ cell count per mm3 382.71 (309.34,
456.09)
Patients exposed to protease inhibitors
(previous and current)
66.21 (59.77, 72.65)
Duration of therapy (years) 4.01 (0.95, 7.07)




Patients exposed to nucleoside
reverse-transcriptase inhibitors
84.23 (74.15, 94.31)
aAll data reported as mean or percentages.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Methodological evaluation and quality
appraisal of selected studies
11 studies (%)
Region of origin 1 Africa (10%)
4 Europe (36%)
5 North America (45%)
1 worldwide (10%)
Location of the study
One centre 5 (45%)
Multicentre 6 (55%)




Clinical database 10 (91%)
Organizational database 1 (9%)
Risk of analytical bias
Low 3 (28%)
Medium 8 (72%)
Risk of selection bias
Low 7 (72%)
Medium 4 (28%)












Very high 1 (10%)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 4 Acute coronary syndrome presentation,
angiographic findings, and revascularization strategies
Pooled analysis
(95% CI)a








One-vessel disease 52.83 (34.83, 70.83)




Coronary artery bypass graft 11.80 (4.32, 19.28)
aAll data reported as mean or percentages.
Figure 2 In-hospital and long-term outcomes. *Up to 30 days.
**Follow-up of 25.50 (11.25, 42 months, 95% CI).
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Moreover, pooled analysis of two25,28 studies reporting the inci-
dence of acute myocardial infarction in patients exposed to prote-
ase inhibitors showed an overall significant risk of 2.68 (odds ratio
1.89, 3.89; 95% CI).
Discussion
Nowadays, HIV-infected patients live longer owing to more effect-
ive antiretroviral therapy. At the same time, while this population
becomes older, the cardiovascular risk of morbidity and death
increases, and also the prevalence of chronic conditions related
to this disease. With our systematic review and meta-analysis,
we intended to summarize available data about risk factors, angio-
graphic and clinical presentation at admission, and safety of anti-
retroviral therapy, reporting the current knowledge about the
physiopathology of HIV infection.
The risk of coronary heart disease in HIV patients is influenced
both from traditional risk factors and from specific features of this
disease. Our meta-analysis shows an overall average incidence of
traditional cardiovascular risk factors, except for diabetes, as can
be expected in a young population. In contrast, in some studies,
cigarette smoking was more prevalent in HIV patients.32 Moreover,
lack of data makes it not possible to analyse the burden of illicit
drug users, which was reported more frequently among
HIV-infected patients and which i’s known to confer a higher
thrombotic risk.33 Nonetheless, as confirmed in the present
work, in various large cohorts, HIV-infected patients showed
high percentages of hypertriglyceridaemia, also related to their
young age.34,35 Many authors36– 38 suggest virus involvement in
the atherosclerosis process through direct effects on cholesterol
processing and transport, attraction and activation of monocytes
at the intimal wall, inducing inflammatory response and endothelial
proliferation.
In our meta-analysis, high rates of in-hospital death were
recorded, probably because of STEMI being the most common
presentation and of frequent occurrence of multivessel.
ST-segment elevation myocardial infarction rates were higher
than in contemporary ACS registries of non-HIV patients,39,40
and similar differences were found for multivessel involvement.
These two factors combined together could easily explain high
rates of in-hospital events in HIV patients.41 The peculiar type of
coronary disease in HIV patients derived both from cardiovascular
risk factors and enhanced from viral pathological process and side
effects of antiretroviral drugs could explain such findings.
Furthermore, our report confirms an important risk of non-fatal
reinfarction after ACS. This finding could be in part explained con-
sidering the young age of the population. Also the prothrombotic
state may be involved in the higher incidence of thrombo-embolic
events and in-stent thrombosis as reported in some studies.19 The
whole mechanisms underlying the disease are probably not com-
pletely clear, but again the HIV infection by itself and the antiretro-
viral therapy associated with chronic inflammation could play a role
in the risk of plaque rupture and atherothrombosis.42,43 As
reported previously,44,45 HIV infection has a direct toxic effect
upon the endothelium and increases interleukin-6 production
that is implicated in the pathogenesis of ACS. Moreover, the
prothrombotic tendency increases proportionally to the viral
load and the CD4 cell count.
No deaths were recorded in the follow-up. This could be due to
many reasons. First, HIV patients may benefit from the use of more
recent therapies and/or aggressive risk factor modification. More-
over, the present meta-analysis included studies obtained from
centres with great experience and expertise in managing patients
with HIV and coronary artery disease.
Finally, we observe that most of the patients presenting with
coronary artery disease are exposed to protease inhibitors or nu-
cleoside reverse-transcriptase inhibitors. In the pooled analysis, we
are able to include only the protease inhibitors therapy, whereas
incomplete data about other therapies are available in the selected
articles. The metabolic syndrome consisting of lipid abnormalities
and insulin resistance induced by the protease inhibitors certainly
plays a role as a cofactor promoting the progression of underlying
coronary lesions eliciting plaque inflammation and rupture.
Anyway, as reported from many authors,46,47 a clear dose–effect
relationship has not been found. The better way to manage
these patients is addressing the modifiable risk factor, keeping
close attention to drug interactions in the presence of a high car-
diovascular risk profile.
Limitations
Our work shares several important limitations. First, data about
the odds ratio for myocardial infarction after proton-pump inhibi-
tors use derived neither from randomized clinical trial nor from
multivariate adjustment, thus being generating hypothesis only,
without the aim of inference. Moreover, we appraised infrequent
events, with all the limits about reporting uncommon outcomes.47
Secondly, no data were pooled about the influence of nucleoside
and non-reverse-transcriptase inhibitors on outcomes, because
of the absence in the included original researches, Thirdly, data
about illicit drugs used, especially cocaine, were present in only
one study,2 and thus, it was not possible to address their influence
on outcomes. Furthermore, in the selected articles, data about
chemokines receptor CCR5 inhibitors48 (entry inhibitors)
therapy were not reported probably because of its recent approval
by the Food and Drug Administration.45 These classes of drugs
could provide new insights because of the critical role of chemo-
kines and their receptors in the pathology of atherosclerosis.
Moreover, no data on cardiac rupture and reperfusion success
were obtained, thus limiting the exploration of mechanisms of
in-hospital death.
Supplementary material
Supplementary material is available at European Heart Journal
online.
Conflict of interest: none declared.
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